2001PubMedRequires access

Uremic toxins: new aspects.

Hörl Wh

Open publisher page 14 citations

Abstract

Clinical signs and symptoms of end-stage renal failure patients are at least in part related to the accumulation of uremic retention solutes and uremic toxins. This article describes abnormalities caused by asymmetric dimethylarginine, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products, homocysteine as well as low and high molecular weight inhibitors of polymorphonuclear leukocytes. Mechanisms for the accumulation of uremic retention solutes and uremic toxins include decrease of renal function, oxidative stress, microinflammation and/or uremia per se resulting in protein modifications with new biological functions.

About this research paper

What this paper is about

Clinical signs and symptoms of end-stage renal failure patients are at least in part related to the accumulation of uremic retention solutes and uremic toxins. This article describes abnormalities caused by asymmetric dimethylarginine, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products, homocysteine as well as low and high molecular weight inhibitors of polymorphonuclear leukocytes. Mechanisms for the accumulation of uremic retention solutes and uremic toxins include decrease of renal function, oxidative stress, microinflammation and/or uremia per se resulting in protein modifications with new biological functions.

Why it matters

OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Clinical signs and symptoms of end-stage renal failure patients are at least in part related to the accumulation of uremic retention solutes and uremic toxins. This article describes abnormalities caused by asymmetric dimethylarginine, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products, homocysteine as well as low and high molecular weight inhibitors of polymorphonuclear leukocytes. Mechanisms for the accumulation of uremic retention solutes and uremic toxins include decrease of renal function, oxidative stress, microinflammation and/or uremia per se resulting in protein modifications with new biological functions.

Key concepts: Uremia, Uremic toxins, Glycation, Medicine, Oxidative stress, Homocysteine, Asymmetric dimethylarginine, End stage renal failure

Related papers

Back to paper searchBrowse research topicsOriginal source
Uremic toxins: new aspects. — Research Paper | ScholarLens